Abstract
Programmed cell death-1 (PD-1) plays an important role in downregulating T lymphocytes but the mechanisms are still poorly understood. This study aimed to explore the role of PD-1 in CD8+ T lymphocyte dysfunction in hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF).
Introduction
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe clinical condition characterized by rapid progression and high mortality rates, often exceeding 50% within 90 days. A defining feature of ACLF is a state of "immune paralysis," where the body's defense mechanisms—particularly CD8+ T lymphocytes—become profoundly dysfunctional. While the Programmed Cell Death-1 (PD-1) pathway is a known "brake" on immune activity, the specific metabolic mechanisms driving this exhaustion in ACLF have remained unclear. This study investigates whether PD-1 mediates immune dysfunction by suppressing glycolysis, the primary energy source for activated T cells.
Methods
The researchers conducted a comparative study involving 30 patients with HBV-ACLF and 30 healthy controls (HCs) recruited from Shanxi Bethune Hospital. The methodology integrated clinical data with laboratory analysis:
- Flow Cytometry: Used to quantify absolute CD8+ T cell counts and measure the expression of PD-1 and the glucose transporter Glut1.
- Metabolic and Functional Assays: Glucose uptake was measured using radioactive tracers. The expression of key glycolytic enzymes (HK2 and PKM2) was analyzed via Western blotting. Functional capacity was assessed by measuring cytokine production (IL-2, IFN-γ, TNF-α) and proliferation markers (Ki67).
- Pathway Activation: To establish causality, the PD-1 pathway was artificially stimulated in vitro using a PD-L1-IgG fusion protein to observe direct effects on T cell metabolism.
Results
PD-1 Upregulation and Metabolic Suppression
The study identified a significant inverse relationship between PD-1 expression and metabolic markers in ACLF patients. Compared to healthy controls, CD8+ T cells in HBV-ACLF patients exhibited significantly higher levels of PD-1 expression.
Concurrently, these cells showed a marked decrease in the expression of Glut1, the primary transporter responsible for glucose uptake. This suggests that the immune cells in ACLF patients are effectively in a state of metabolic starvation.
Functional Consequences of PD-1 Signaling
Experimental activation of the PD-1 pathway in vitro confirmed these clinical observations. Triggering PD-1 led to:
- Reduced Glucose Uptake: Dropping from 2.8 pmol/cell to 2.0 pmol/cell (p < 0.001).
- Enzyme Downregulation: Western blots showed significant suppression of HK2 and PKM2, the engines of the glycolytic pathway.
- Cytokine Collapse: Production of critical immune signals like IL-2 was reduced by more than half (from ~150,586 MFI to ~64,267 MFI).
Discussion
These findings suggest that the immune paralysis observed in HBV-ACLF is an active process mediated by the PD-1 pathway. By inhibiting the glycolytic machinery, PD-1 prevents CD8+ T cells from accessing the energy required to proliferate and combat infection. This "metabolic brake" contributes to the high susceptibility to secondary infections and mortality in ACLF patients.
While this study provides a clear link between PD-1 and metabolic dysfunction in peripheral blood, further research is needed to determine if similar mechanisms occur within the liver tissue itself. Additionally, while PD-1 blockade presents a potential therapeutic target to "restart" the immune system, clinical application must be carefully balanced against the risk of exacerbating liver inflammation.
Summary updated